Skip to Content

ResMed studies show efficacy of PAP therapy

ResMed studies show efficacy of PAP therapy

SAN DIEGO – New ResMed-supported research providing insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits was presented at the American Thoracic Society International Conference.  

The studies were among a total of 26 supported by ResMed in collaboration with leading scientists, including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany. 

Highlights include: 

  • An analysis of data from 27 randomized control trials and non-randomized control studies on the effects of PAP on patients with OSA found mortality was 37% lower on average in patients with PAP-treated OSA vs. untreated OSA. 

  • One study looked at nearly 50,000 adults with COPD who were treated via domiciliary NIV and found long-term home use of NIV was strongly associated with a reduced risk of death. 

  • Another study projected OSA cases in the United States to increase by 27.6% by 2050 in men and women aged 30-70, with an overall prevalence within this group projected to be 26%. 

  • Another study found GLP-1s did not lead to higher discontinuation rates of PAP therapy, rather to higher levels of PAP therapy use.


To comment on this post, please log in to your account or set up an account now.